Ahmedabad-based Sun Pharma today announced that it received an approval from US Food and Drug Administration to market a generic version of anti-depressant Venlafaxine Hydrochloride Extended Release Tablets.
The generic tablets of Sun Pharma are equivalent therapeutically to Osmotica's Venlafaxine Hydrochloride, in three strengths. This drug has been indicated for the management of major depressive disorders. The product is expected to hit the market shortly.
Sun Pharma has interests in branded generics as well as generics, in India, US and several markets. In India, the company has a good presence in therapy areas like psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and opthalmology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app